Effects of a Probiotic Formulation on Seasonal Allergic Rhinitis in Adults-A Randomized Double-Blind Placebo-Controlled Trial: The Probiotics for Hay Fever Trial.
T-helper cell ratio
hay fever
probiotics
quality of life
seasonal allergic rhinitis
symptoms
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
02
03
2022
accepted:
21
04
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
10
6
2022
Statut:
epublish
Résumé
Seasonal-allergic-rhinitis (hay fever) affects approximately 4.6 million (20%) Australians each year. Hay fever manifests as runny/blocked nose and often itchy/sore/swollen eyes, with symptoms greatly impacting the quality of life. Rescue medications such as antihistamines are often needed to restore function, but they may trigger some other unwanted side effects. Probiotics have shown promise to reduce hay fever symptoms. In this randomized double-blind placebo-controlled 12-week trial, we aimed to assess the tolerability and efficacy of the probiotic formula "NC-Seasonal-Biotic" on symptoms, quality-of-life, and immunological and microbial factors. Adults, who had previously suffered from hay fever symptoms, were screened for eligibility and randomly allocated to probiotic or placebo trial powder. Treatment effectiveness was assessed by questionnaires, daily total-nasal-symptom-score, and weekly rhinoconjunctivitis quality-of-life questionnaire. Secondary outcome measures included immunological parameters such as T-cell immunity (Th1/Th2 ratio) and the stool-microbiome analysis. Tolerability was assessed weekly by the gastrointestinal symptom scale. Recruitment and follow-up were challenging around the 2020/2021 hay fever season in Melbourne, Australia, due to the harsh COVID-19 restrictions and extended lockdowns. Out of the 82 adults enrolled in this study, 75% participated ( Our study suggests the probiotic formula "NC-Seasonal-Biotic," taken for 10-12 weeks, as effective in reducing hay fever symptoms, such as runny nose and itchy eyes, and improved the quality-of-life and immunological parameters while being well tolerated. [www.ClinicalTrials.gov], identifier [ACTRN126200 01078943].
Sections du résumé
Background
UNASSIGNED
Seasonal-allergic-rhinitis (hay fever) affects approximately 4.6 million (20%) Australians each year. Hay fever manifests as runny/blocked nose and often itchy/sore/swollen eyes, with symptoms greatly impacting the quality of life. Rescue medications such as antihistamines are often needed to restore function, but they may trigger some other unwanted side effects. Probiotics have shown promise to reduce hay fever symptoms.
Objective
UNASSIGNED
In this randomized double-blind placebo-controlled 12-week trial, we aimed to assess the tolerability and efficacy of the probiotic formula "NC-Seasonal-Biotic" on symptoms, quality-of-life, and immunological and microbial factors.
Methods
UNASSIGNED
Adults, who had previously suffered from hay fever symptoms, were screened for eligibility and randomly allocated to probiotic or placebo trial powder. Treatment effectiveness was assessed by questionnaires, daily total-nasal-symptom-score, and weekly rhinoconjunctivitis quality-of-life questionnaire. Secondary outcome measures included immunological parameters such as T-cell immunity (Th1/Th2 ratio) and the stool-microbiome analysis. Tolerability was assessed weekly by the gastrointestinal symptom scale.
Results
UNASSIGNED
Recruitment and follow-up were challenging around the 2020/2021 hay fever season in Melbourne, Australia, due to the harsh COVID-19 restrictions and extended lockdowns. Out of the 82 adults enrolled in this study, 75% participated (
Conclusion
UNASSIGNED
Our study suggests the probiotic formula "NC-Seasonal-Biotic," taken for 10-12 weeks, as effective in reducing hay fever symptoms, such as runny nose and itchy eyes, and improved the quality-of-life and immunological parameters while being well tolerated.
Clinical Trial Registration
UNASSIGNED
[www.ClinicalTrials.gov], identifier [ACTRN126200 01078943].
Identifiants
pubmed: 35677549
doi: 10.3389/fnut.2022.887978
pmc: PMC9169690
doi:
Types de publication
Journal Article
Langues
eng
Pagination
887978Informations de copyright
Copyright © 2022 Ried, Travica, Paye and Sali.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Exp Allergy. 2000 Jan;30(1):132-40
pubmed: 10606940
Clin Exp Immunol. 2010 Jun;160(3):295-304
pubmed: 20345982
Qual Life Res. 1998 Jan;7(1):75-83
pubmed: 9481153
J Allergy Clin Immunol. 1997 Jul;100(1):16-22
pubmed: 9257782
Am J Clin Nutr. 2017 Mar;105(3):758-767
pubmed: 28228426
Allergy. 2014 Jul;69(7):854-67
pubmed: 24761804
Biosci Biotechnol Biochem. 2010;74(9):1869-77
pubmed: 20834165
Allergy. 2004 Apr;59(4):406-14
pubmed: 15005764
Am J Rhinol Allergy. 2016 Sep 1;30(5):157-175
pubmed: 27442711
Microb Cell Fact. 2013 Jul 23;12:71
pubmed: 23876056
J Dairy Sci. 2005 Feb;88(2):527-33
pubmed: 15653517
Int J Food Microbiol. 2009 Jan 15;128(3):429-34
pubmed: 18977549
Int Arch Allergy Immunol. 2007;143(1):75-82
pubmed: 17199093
Allergy Asthma Proc. 2009 Jul-Aug;30(4):397-405
pubmed: 19772761
EBioMedicine. 2015 Nov 27;3:172-179
pubmed: 26870828